Natural Cycles Raises $55M in Series C Funding

Natural Cycles Secures $55 Million in Series C Funding for Birth Control App

Natural Cycles, a leading women's health company and creator of the first FDA-approved birth control app, has successfully raised $55 million in Series C funding, bringing its total funding to over $95 million. The digital contraceptive app, developed by co-founders Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, has garnered a global user base of over three million. The recent funding, primarily led by Lauxera Capital Partners with contributions from Point72 Private Investments and J.P. Morgan, aims to drive the company's expansion in commercial acceleration, new product development, and healthcare reimbursement automation. Moreover, Samuel Levy from Lauxera Capital Partners is set to join the board of Natural Cycles, further strengthening the company's strategic roadmap for delivering hormone-free birth control solutions.

Key Takeaways

• Natural Cycles secures $55 million in Series C funding, totaling over $95 million in funding.
• The company is recognized as the first to offer a digital contraceptive app cleared by multiple global regulators.
• Natural Cycles is focused on broadening hormone-free birth control access and advancing women's health tech.
• The recently launched NC° Postpartum feature aims to support new mothers within the app.
• Lauxera Capital Partners spearheaded the funding, with Samuel Levy joining the Board of Directors.

Analysis

The $55 million Series C funding secured by Natural Cycles underscores the growing investor confidence in digital health solutions. This infusion is expected to hasten market expansion and product innovation, particularly in hormone-free contraception. The involvement of prominent investors such as Lauxera Capital Partners and J.P. Morgan signals a strategic move toward healthcare automation and wider insurance coverage. In the short term, an increased user base and product improvements, like the NC° Postpartum feature, are anticipated. Looking ahead, this funding could redefine contraceptive options and wield influence over healthcare policy, impacting millions worldwide.

Did You Know?

• Series C Funding: This phase in the venture capital funding process typically indicates a company's proven viability and its intention to achieve significant scaling. Series C funding rounds are primarily geared toward further business expansion, often with the goal of market dominance or venturing into new markets.
• Lauxera Capital Partners: A private equity firm specializing in investments within the healthcare and life sciences sectors. Apart from providing financial capital, they also offer strategic guidance to facilitate companies' growth and success in their respective markets.
• Healthcare Reimbursement Automation: This refers to the utilization of technology to automate the process of claiming and receiving payments from health insurance companies for services rendered. Automation in this domain can substantially reduce administrative costs and enhance the efficiency of billing processes.